UBS Group’s Nuvalent NUVL Stock Holding History

UBS Group’s Portfolio NUVL Stock Details NUVL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$9.26M	Buy	+75,000	New	+$8.07M	﹤0.01%	3529

Other funds holding NUVL

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

UBS Group's NUVL Position: Q2 2026 in Review

UBS Group reduced its Nuvalent (NUVL) stake by 77% in Q2 2026, selling an estimated $29.9M and leaving 84,659 shares worth $10.5M. The position accounts for ﹤0.01% of the portfolio, ranked #3389.

UBS Group first reported a position in NUVL in Q3 2021 and has held it in 18 quarters since. The position peaked at $40.1M in Q4 2025. 293 funds tracked by Wall St. Rank hold NUVL as of Q2 2026.

UBS Group held 84,659 shares of Nuvalent worth $10.5M as of Q2 2026.
UBS Group sold 278,439 Nuvalent shares in Q2 2026, an estimated $29.9M.
Nuvalent made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #3389 holding.
UBS Group first reported a position in Nuvalent in Q3 2021 and has held it in 18 quarters since.
UBS Group's Nuvalent position peaked at $40.1M in Q4 2025.
293 funds tracked by Wall St. Rank held Nuvalent as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.